Menactra®

Meningococcal Conjugate Vaccine Against N. meningitidis Serogroups A, C, W, Y (Polysaccharide, Conjugated).¹

Indications

Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y in individuals aged 9 months through 55 years inclusive.¹

Age of Use

For children from 9 months of age and adults up to 55 years inclusive.¹

Vaccination Schedule

Children 9 to 23 months: A 2-dose schedule with an interval of at least 3 months.¹
Individuals 2 to 55 years: A single dose.¹

Manufacturing and Registration

Marketing Authorization Holder: Sanofi Pasteur Inc.¹
Registered in the Russian Federation since 2014.²
Manufactured at the Nanolek Biomedical Complex since 2022.³

Official Documents

1.
Summary of Product Characteristics for Menactra®.
Accessed: 08.07.2025.
2.
State Register of Medicines.
Accessed: 25.07.2025.
3.
Nanolek and Sanofi produced the first batch of the meningococcal vaccine at the plant in the Kirov Region.
Accessed: 08.07.2025.

News

10 March 2022 Nanolek teams up with Sanofi to produce the first batch of meningococcal vaccines at the plant in the Kirov region 4 October 2021 Sanofi Pasteur and Nanolek Sign an Agreement on Domestic Production of Meningitis Vaccines to Produce up to 3.5 Million Doses Annually in Russia Starting From 2022